Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia

NCT00562328 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

BIOLOGICAL: Alemtuzumab
BIOLOGICAL: Rituximab
BIOLOGICAL: Sargramostim

Sponsor

Mayo Clinic

Collaborators

[object Object]